Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission
NCT00546494
Last updated date
ABOUT THIS STUDY
This is a study to determine the utility of Effexor® (venlafaxine) in achieving response,
including time to response, maintaining remission, and time to remission as measured by the
17-item Hamilton Rating Scale for Depression (HAM-D) and to determine the utility of Effexor®
(venlafxine) on the various cluster of symptom scales in the 17-item HAM-D.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Depression
Sex
Females and Males
Age
0 +
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
DepressionAction-Based Cognitive Remediation to Improve Vocational Outcomes in Depression
NCT02535390
- Kingston, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
DepressionA Pilot Study of eHealth Tools in a Tertiary-care Setting
NCT03762460
- Vancouver, British Columbia
ALL GENDERS
19 Years+
years
MULTIPLE SITES
DepressionEvaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
NCT00200902
- Los Angeles, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
DepressionAn Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression
NCT00122083
- Oxford, Oxfordshire
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission | |||
Official Title ICMJE | A Study Of The Utility Of Effexor® (Venlafaxine) In Achieving Response And Maintaining Remission Among Taiwanese Patients With Depression | |||
Brief Summary | This is a study to determine the utility of Effexor® (venlafaxine) in achieving response, including time to response, maintaining remission, and time to remission as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D) and to determine the utility of Effexor® (venlafxine) on the various cluster of symptom scales in the 17-item HAM-D. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Depression | |||
Intervention ICMJE | Drug: Effexor® (Venlafaxine) | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 350 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | March 2005 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | INCLUSION CRITERIA:
EXCLUSION CRITERIA:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | Child, Adult, Older Adult | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00546494 | |||
Other Study ID Numbers ICMJE | 0600B-101547 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Verification Date | October 2007 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |